Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.
MTAP loss is among the most common potentially targetable driver mutations in non-small cell lung cancer (NSCLC), supporting ongoing early-phase trials.
In resectable non-small cell lung cancer, major pathologic response is linked to spatial enrichment of T- and B-cell activation pathways and CD8+ T-cell infiltration, with an MPR rate of 37.5%.
Spatial profiling of resected non-small cell lung cancer tumors and lymph nodes identified immune subtypes and a gene signature linked to improved outcomes.